Increased Profitability
EBITDA increased by 11.9% to EUR 63.9 million, with the EBITDA margin improving by 1.6 percentage points to 12.6%.
Positive Earnings After Tax
Earnings after tax turned positive after divesting the medical business, which previously caused losses.
Strong Free Cash Flow
Free cash flow reached EUR 22.4 million by end of September, providing solid firepower for growth investments.
Improvement in Industrial Applications
EBITDA margin improved by almost 3 percentage points to 19% in the Industrial Applications division.
Resilience in Engineered Applications
Sales in Engineered Applications were up by 12% despite pricing pressure.
Commitment to Guidance
Confirmed 2024 EBITDA guidance of around EUR 80 million and CapEx of around EUR 70 million.